AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization

Area of Science:

• Oncology
• Molecular Biology
• Gynecologic Oncology

Background:

• High-grade serous ovarian cancer (HGSOC) has poor outcomes due to therapy resistance and heterogeneity.
• Combinatorial therapies are needed to improve HGSOC patient survival.
• The role of AKT isoforms in HGSOC and their synergy with PARP inhibitors requires clarification.

Purpose of the Study:

• To investigate the expression of AKT isoforms in HGSOC.
• To correlate AKT isoform expression and ratios with clinicopathological features and patient survival.
• To define potential patient subsets for AKT and PARP inhibitor combination therapy.

Main Methods:

• Retrospective analysis of archival HGSOC tissue samples.
• Quantitative assessment of AKT isoform expression using RT-droplet digital PCR (ddPCR).
• Statistical analysis of AKT isoform expression, ratios (AKT1/AKT2, AKT1/AKT3), and clinicopathological parameters.

Main Results:

• Four distinct AKT classes were defined based on AKT isoform ratios.
• These AKT classes showed significant associations with patient survival, tumor morphology, and BRCA1 expression.
• High AKT3 expression correlated with classic HGSOC features, low mitosis counts, and psammoma bodies.

Conclusions:

• AKT isoform expression patterns provide novel insights into HGSOC heterogeneity.
• Defined AKT classes may help identify HGSOC patients who can benefit from AKT and PARP inhibitor combinations.
• This research supports personalized treatment strategies for HGSOC in future clinical trials.